Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine

Frank R. Jones; Elizabeth S. Gabitzsch; Younong Xu; Joseph P. Balint; Viktoriya Borisevich; Jennifer Smith; Jeanon Smith; Bi Hung Peng; Aida Walker; Magda Salazar; Slobodan Paessler

doi:10.1016/j.vaccine.2011.07.073

Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine

Frank R. Jones, Elizabeth S. Gabitzsch, Younong Xu, Joseph P. Balint, Viktoriya Borisevich, Jennifer Smith, Jeanon Smith, Bi Hung Peng, Aida Walker, Magda Salazar, Slobodan Paessler

Pathology

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Vaccines against emerging pathogens such as the 2009 H1N1 pandemic virus can benefit from current technologies such as rapid genomic sequencing to construct the most biologically relevant vaccine. A novel platform (Ad5 [E1-, E2b-]) has been utilized to induce immune responses to various antigenic targets. We employed this vector platform to express hemagglutinin (HA) and neuraminidase (NA) genes from 2009 H1N1 pandemic viruses. Inserts were consensuses sequences designed from viral isolate sequences and the vaccine was rapidly constructed and produced. Vaccination induced H1N1 immune responses in mice, which afforded protection from lethal virus challenge. In ferrets, vaccination protected from disease development and significantly reduced viral titers in nasal washes. H1N1 cell mediated immunity as well as antibody induction correlated with the prevention of disease symptoms and reduction of virus replication. The Ad5 [E1-, E2b-] should be evaluated for the rapid development of effective vaccines against infectious diseases.

Original language	English (US)
Pages (from-to)	7020-7026
Number of pages	7
Journal	Vaccine
Volume	29
Issue number	40
DOIs	https://doi.org/10.1016/j.vaccine.2011.07.073
State	Published - Sep 16 2011

Keywords

Ad5 [E1-, E2b-]
Adenovirus vector
Cell mediated immunity
H1N1 vaccine
Hemagglutinin
Horizontal transmission
Influenza
Neuraminidase
Pandemic
Viral shedding

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2011.07.073

Cite this

Jones, F. R., Gabitzsch, E. S., Xu, Y., Balint, J. P., Borisevich, V., Smith, J., Smith, J., Peng, B. H., Walker, A., Salazar, M., & Paessler, S. (2011). Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine. Vaccine, 29(40), 7020-7026. https://doi.org/10.1016/j.vaccine.2011.07.073

@article{ae6533fcc9f34101949589fe43b0e7cc,

title = "Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine",

abstract = "Vaccines against emerging pathogens such as the 2009 H1N1 pandemic virus can benefit from current technologies such as rapid genomic sequencing to construct the most biologically relevant vaccine. A novel platform (Ad5 [E1-, E2b-]) has been utilized to induce immune responses to various antigenic targets. We employed this vector platform to express hemagglutinin (HA) and neuraminidase (NA) genes from 2009 H1N1 pandemic viruses. Inserts were consensuses sequences designed from viral isolate sequences and the vaccine was rapidly constructed and produced. Vaccination induced H1N1 immune responses in mice, which afforded protection from lethal virus challenge. In ferrets, vaccination protected from disease development and significantly reduced viral titers in nasal washes. H1N1 cell mediated immunity as well as antibody induction correlated with the prevention of disease symptoms and reduction of virus replication. The Ad5 [E1-, E2b-] should be evaluated for the rapid development of effective vaccines against infectious diseases.",

keywords = "Ad5 [E1-, E2b-], Adenovirus vector, Cell mediated immunity, H1N1 vaccine, Hemagglutinin, Horizontal transmission, Influenza, Neuraminidase, Pandemic, Viral shedding",

author = "Jones, {Frank R.} and Gabitzsch, {Elizabeth S.} and Younong Xu and Balint, {Joseph P.} and Viktoriya Borisevich and Jennifer Smith and Jeanon Smith and Peng, {Bi Hung} and Aida Walker and Magda Salazar and Slobodan Paessler",

note = "Funding Information: The authors want to thank Ms. Carol Jones for her contribution and management of the study and Ms. Stephanie Balcaitis for excellent technical assistance. This study was funded in part by NIH-NIAID grant 2R44AI1071733 awarded to FRJ and Etubics Corporation. ",

year = "2011",

month = sep,

day = "16",

doi = "10.1016/j.vaccine.2011.07.073",

language = "English (US)",

volume = "29",

pages = "7020--7026",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "40",

}

TY - JOUR

T1 - Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine

AU - Jones, Frank R.

AU - Gabitzsch, Elizabeth S.

AU - Xu, Younong

AU - Balint, Joseph P.

AU - Borisevich, Viktoriya

AU - Smith, Jennifer

AU - Smith, Jeanon

AU - Peng, Bi Hung

AU - Walker, Aida

AU - Salazar, Magda

AU - Paessler, Slobodan

N1 - Funding Information: The authors want to thank Ms. Carol Jones for her contribution and management of the study and Ms. Stephanie Balcaitis for excellent technical assistance. This study was funded in part by NIH-NIAID grant 2R44AI1071733 awarded to FRJ and Etubics Corporation.

PY - 2011/9/16

Y1 - 2011/9/16

N2 - Vaccines against emerging pathogens such as the 2009 H1N1 pandemic virus can benefit from current technologies such as rapid genomic sequencing to construct the most biologically relevant vaccine. A novel platform (Ad5 [E1-, E2b-]) has been utilized to induce immune responses to various antigenic targets. We employed this vector platform to express hemagglutinin (HA) and neuraminidase (NA) genes from 2009 H1N1 pandemic viruses. Inserts were consensuses sequences designed from viral isolate sequences and the vaccine was rapidly constructed and produced. Vaccination induced H1N1 immune responses in mice, which afforded protection from lethal virus challenge. In ferrets, vaccination protected from disease development and significantly reduced viral titers in nasal washes. H1N1 cell mediated immunity as well as antibody induction correlated with the prevention of disease symptoms and reduction of virus replication. The Ad5 [E1-, E2b-] should be evaluated for the rapid development of effective vaccines against infectious diseases.

AB - Vaccines against emerging pathogens such as the 2009 H1N1 pandemic virus can benefit from current technologies such as rapid genomic sequencing to construct the most biologically relevant vaccine. A novel platform (Ad5 [E1-, E2b-]) has been utilized to induce immune responses to various antigenic targets. We employed this vector platform to express hemagglutinin (HA) and neuraminidase (NA) genes from 2009 H1N1 pandemic viruses. Inserts were consensuses sequences designed from viral isolate sequences and the vaccine was rapidly constructed and produced. Vaccination induced H1N1 immune responses in mice, which afforded protection from lethal virus challenge. In ferrets, vaccination protected from disease development and significantly reduced viral titers in nasal washes. H1N1 cell mediated immunity as well as antibody induction correlated with the prevention of disease symptoms and reduction of virus replication. The Ad5 [E1-, E2b-] should be evaluated for the rapid development of effective vaccines against infectious diseases.

KW - Ad5 [E1-, E2b-]

KW - Adenovirus vector

KW - Cell mediated immunity

KW - H1N1 vaccine

KW - Hemagglutinin

KW - Horizontal transmission

KW - Influenza

KW - Neuraminidase

KW - Pandemic

KW - Viral shedding

UR - http://www.scopus.com/inward/record.url?scp=80052327605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052327605&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.07.073

DO - 10.1016/j.vaccine.2011.07.073

M3 - Article

C2 - 21821082

AN - SCOPUS:80052327605

SN - 0264-410X

VL - 29

SP - 7020

EP - 7026

JO - Vaccine

JF - Vaccine

IS - 40

ER -

Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this